Flotetuzumab Biosimilar Bispecific scFv Antibody (CD123 × CD3) for Research

Cat No.: GMP-Bios-ab-218

Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Flotetuzumab (INN; development code MGD006) is a bispecific antibody designed for the treatment of acute myeloid leukemia.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-218-1mg 1mg
GMP-Bios-ab-218-10mg 10mg
GMP-Bios-ab-218-100mg 100mg
GMP-Bios-ab-218-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody
INN Name Flotetuzumab
TargetIL3RA;CD3E
FormatBispecific scFv with Crossover
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2017
Year Recommended2018
CompaniesMacroGenics;Servier
Conditions Approvedna
Conditions ActiveAcute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma
Conditions Discontinuedna
Development TechDual-Affinity Re-Targeting Technology



About target - IL3RA

1. Protein Interleukin-3 receptor subunit alpha

2. Gene IL3RA

3. Organism Homo sapiens (Human)

Function
This is a receptor for interleukin-3.

Miscellaneous
The gene coding for this protein is located in the pseudoautosomal region 1 (PAR1) of X and Y chromosomes.